Online inquiry

IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2090MR)

This product GTTS-WQ2090MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ2090MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2867MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-761
GTTS-WQ13969MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ15048MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ5887MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CIFN
GTTS-WQ6887MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ2400MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 110
GTTS-WQ13372MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ10378MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2062430
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW